Roche Decides Not to Exercise Solid Tumor Option with SQZ

It’s been a tough year for SQZ Biotechnologies. The beleaguered cell therapy company announced Tuesday that partner Roche wouldn’t be exercising its solid tumor option with SQZ, despite promising Phase I results, sending the Massachusetts-based biotech scrambling to find alternative partnerships.